Protein kinases as targets for antiparasitic chemotherapy drugs.
Parasitic protozoa infecting humans have a great impact on public health, especially in the developing countries. In many instances, the parasites have developed resistance against available chemotherapeutic agents, making the search for alternative drugs a priority. In line with the current interest in Protein Kinase (PK) inhibitors as potential drugs against a variety of diseases, the possibility that PKs may represent targets for novel anti-parasitic agents is being explored. Research into parasite PKs has benefited greatly from genome and EST sequencing projects, with the genomes from a few species fully sequenced (notably that from the malaria parasite Plasmodium falciparum) and several more under way, the structural features that are important to design specific inhibitors against these PKs will be reviewed in the present work.
Canduri
Fernanda
F
Universidade Federal de Mato Grosso do Sul, Centro de Ciências Biológicas e da Saúde, Departamento de Morfofisiologia-Laboratório de Bioquímica, Caixa Postal, Campo Grande-MS, Brazil. fcanduri@yahoo.com.br
Perez
Patrícia Cardoso
PC
Caceres
Rafael A
RA
de Azevedo
Walter F
WF
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000977:Antiparasitic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D011494:Protein Kinases / Q000737:chemistry / Q000378:metabolism*
D000970:Antineoplastic Agents; D000977:Antiparasitic Agents; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases